Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1868 1
1869 1
1870 1
1873 1
1874 1
1876 1
1877 1
1880 1
1881 1
1882 1
1883 2
1885 2
1888 4
1889 2
1890 2
1893 4
1894 7
1895 3
1896 3
1898 3
1899 1
1900 2
1901 3
1902 2
1903 4
1905 1
1906 1
1910 1
1911 1
1913 2
1914 5
1915 3
1916 1
1918 2
1919 2
1920 1
1921 1
1922 4
1923 1
1924 1
1925 4
1926 6
1927 13
1928 12
1929 11
1930 12
1931 12
1933 2
1934 2
1935 1
1936 5
1937 2
1938 1
1939 2
1941 1
1942 3
1944 1
1945 5
1946 11
1947 17
1948 20
1949 20
1950 16
1951 13
1952 21
1953 20
1954 12
1955 18
1956 14
1957 19
1958 17
1959 19
1960 21
1961 28
1962 10
1963 17
1964 36
1965 30
1966 31
1967 26
1968 43
1969 35
1970 57
1971 55
1972 49
1973 56
1974 69
1975 62
1976 67
1977 72
1978 72
1979 74
1980 83
1981 71
1982 86
1983 69
1984 99
1985 99
1986 97
1987 70
1988 95
1989 96
1990 88
1991 129
1992 111
1993 133
1994 107
1995 131
1996 126
1997 130
1998 134
1999 121
2000 147
2001 146
2002 187
2003 149
2004 183
2005 210
2006 226
2007 195
2008 239
2009 285
2010 276
2011 320
2012 336
2013 367
2014 330
2015 357
2016 481
2017 463
2018 461
2019 476
2020 576
2021 614
2022 592
2023 577
2024 196

Text availability

Article attribute

Article type

Publication date

Search Results

10,808 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D. Kaye KS, et al. Among authors: miller a. Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11. Lancet Infect Dis. 2023. PMID: 37182534 Clinical Trial.
On the genetic basis of tail-loss evolution in humans and apes.
Xia B, Zhang W, Zhao G, Zhang X, Bai J, Brosh R, Wudzinska A, Huang E, Ashe H, Ellis G, Pour M, Zhao Y, Coelho C, Zhu Y, Miller A, Dasen JS, Maurano MT, Kim SY, Boeke JD, Yanai I. Xia B, et al. Among authors: miller a. Nature. 2024 Feb;626(8001):1042-1048. doi: 10.1038/s41586-024-07095-8. Epub 2024 Feb 28. Nature. 2024. PMID: 38418917 Free PMC article.
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE; DISCOMS investigators. Corboy JR, et al. Among authors: miller ae. Lancet Neurol. 2023 Jul;22(7):568-577. doi: 10.1016/S1474-4422(23)00154-0. Lancet Neurol. 2023. PMID: 37353277 Clinical Trial.
Beyond the symptom: the biology of fatigue.
Raizen DM, Mullington J, Anaclet C, Clarke G, Critchley H, Dantzer R, Davis R, Drew KL, Fessel J, Fuller PM, Gibson EM, Harrington M, Ian Lipkin W, Klerman EB, Klimas N, Komaroff AL, Koroshetz W, Krupp L, Kuppuswamy A, Lasselin J, Lewis LD, Magistretti PJ, Matos HY, Miaskowski C, Miller AH, Nath A, Nedergaard M, Opp MR, Ritchie MD, Rogulja D, Rolls A, Salamone JD, Saper C, Whittemore V, Wylie G, Younger J, Zee PC, Craig Heller H. Raizen DM, et al. Among authors: miller ah. Sleep. 2023 Sep 8;46(9):zsad069. doi: 10.1093/sleep/zsad069. Sleep. 2023. PMID: 37224457 Review.
Denouement.
Miller AM. Miller AM. J Palliat Med. 2023 Aug;26(8):1153. doi: 10.1089/jpm.2023.0120. J Palliat Med. 2023. PMID: 37579236 No abstract available.
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Kaul I, et al. Among authors: miller ac. Lancet. 2024 Jan 13;403(10422):160-170. doi: 10.1016/S0140-6736(23)02190-6. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104575 Clinical Trial.
Bertolotti Syndrome.
Miller AE, Zhang A. Miller AE, et al. 2023 Jul 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jul 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 36251807 Free Books & Documents.
Multidisciplinary bronchopulmonary dysplasia care.
Miller AN, Shepherd EG, El-Ferzli G, Nelin LD. Miller AN, et al. Expert Rev Respir Med. 2023 Jul-Dec;17(11):989-1002. doi: 10.1080/17476348.2023.2283120. Epub 2023 Dec 26. Expert Rev Respir Med. 2023. PMID: 37982177 Review.
Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors.
Brightman SE, Becker A, Thota RR, Naradikian MS, Chihab L, Zavala KS, Ramamoorthy Premlal AL, Griswold RQ, Dolina JS, Cohen EEW, Miller AM, Peters B, Schoenberger SP. Brightman SE, et al. Among authors: miller am. Nat Immunol. 2023 Aug;24(8):1345-1357. doi: 10.1038/s41590-023-01543-9. Epub 2023 Jul 3. Nat Immunol. 2023. PMID: 37400675 Free PMC article.
10,808 results
You have reached the last available page of results. Please see the User Guide for more information.